DK2170877T5 - Substituerede (oxazolidinon-5-yl-methyl)-2-thiophen-carboxamider og anvendelsen heraf på området for koagulering - Google Patents

Substituerede (oxazolidinon-5-yl-methyl)-2-thiophen-carboxamider og anvendelsen heraf på området for koagulering

Info

Publication number
DK2170877T5
DK2170877T5 DK08773372.1T DK08773372T DK2170877T5 DK 2170877 T5 DK2170877 T5 DK 2170877T5 DK 08773372 T DK08773372 T DK 08773372T DK 2170877 T5 DK2170877 T5 DK 2170877T5
Authority
DK
Denmark
Prior art keywords
oxazolidinon
coagulation
substituted
methyl
field
Prior art date
Application number
DK08773372.1T
Other languages
English (en)
Other versions
DK2170877T3 (da
Inventor
Joachim Krueger
Susanne Roehrig
Holger Paulsen
Swen Allerheiligen
Stefan Heitmeier
Mark Jean Gnoth
Ulrich Rester
Elke Dittrich-Wengenroth
Uwe Saatmann
Adrian Tersteegen
Marcus Bauser
Dirk Heimbach
Christoph Gerdes
Degenfeld Georges Von
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39731148&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2170877(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of DK2170877T3 publication Critical patent/DK2170877T3/da
Application granted granted Critical
Publication of DK2170877T5 publication Critical patent/DK2170877T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
DK08773372.1T 2007-06-20 2008-06-07 Substituerede (oxazolidinon-5-yl-methyl)-2-thiophen-carboxamider og anvendelsen heraf på området for koagulering DK2170877T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007028319A DE102007028319A1 (de) 2007-06-20 2007-06-20 Substituierte Oxazolidinone und ihre Verwendung
PCT/EP2008/004562 WO2008155032A1 (de) 2007-06-20 2008-06-07 Substituierte (oxazolidinon-5-yl-methyl) -2-thiophen-carboxamide und ihre verwendung im gebiet der blutgerinnung

Publications (2)

Publication Number Publication Date
DK2170877T3 DK2170877T3 (da) 2013-02-11
DK2170877T5 true DK2170877T5 (da) 2013-03-04

Family

ID=39731148

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08773372.1T DK2170877T5 (da) 2007-06-20 2008-06-07 Substituerede (oxazolidinon-5-yl-methyl)-2-thiophen-carboxamider og anvendelsen heraf på området for koagulering

Country Status (42)

Country Link
US (2) US8383822B2 (da)
EP (1) EP2170877B1 (da)
JP (1) JP5537421B2 (da)
KR (1) KR101535312B1 (da)
CN (1) CN101821259B (da)
AR (2) AR066981A1 (da)
AU (1) AU2008266525B8 (da)
BR (1) BRPI0813736A2 (da)
CA (1) CA2692166C (da)
CL (1) CL2008001691A1 (da)
CO (1) CO6251281A2 (da)
CR (1) CR11168A (da)
CU (1) CU23820A3 (da)
CY (1) CY1113580T1 (da)
DE (1) DE102007028319A1 (da)
DK (1) DK2170877T5 (da)
DO (1) DOP2009000285A (da)
EC (1) ECSP099807A (da)
ES (1) ES2397799T3 (da)
GT (1) GT200900319A (da)
HN (1) HN2009003424A (da)
HR (1) HRP20130072T1 (da)
IL (1) IL202351A (da)
JO (1) JO2798B1 (da)
MA (1) MA31535B1 (da)
MX (1) MX2009013711A (da)
MY (1) MY150931A (da)
NZ (1) NZ581540A (da)
PA (1) PA8784301A1 (da)
PE (1) PE20090332A1 (da)
PL (1) PL2170877T3 (da)
PT (1) PT2170877E (da)
RS (1) RS52639B (da)
RU (1) RU2481345C2 (da)
SG (1) SG182220A1 (da)
SI (1) SI2170877T1 (da)
SV (1) SV2009003435A (da)
TN (1) TN2009000503A1 (da)
TW (1) TWI413642B (da)
UA (1) UA98793C2 (da)
UY (1) UY31133A1 (da)
WO (1) WO2008155032A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006039589A1 (de) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
DE102007028407A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102010028362A1 (de) 2010-04-29 2011-11-03 Bayer Schering Pharma Aktiengesellschaft Herstellverfahren
CN102464658B (zh) * 2010-11-03 2014-04-16 天津药物研究院 噁唑烷酮衍生物及其制备方法和用途
WO2012098089A1 (en) 2011-01-19 2012-07-26 Bayer Pharma Aktiengesellschaft Binding proteins to inhibitors of coagulation factors
CN103626749A (zh) * 2012-08-21 2014-03-12 苏州泽璟生物制药有限公司 取代的噁唑烷酮化合物和包含该化合物的药物组合物及其用途
WO2014183667A1 (zh) * 2013-05-17 2014-11-20 天津药物研究院 一种噁唑烷酮衍生物的乙酸溶剂化物及其制备方法和用途
CN103242307B (zh) * 2013-05-17 2015-08-12 天津药物研究院有限公司 一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途
CN103232446B (zh) * 2013-05-17 2015-09-23 天津药物研究院 一种噁唑烷酮衍生物晶型ⅱ及其制备方法和用途

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
DE4319041A1 (de) 1992-10-23 1994-04-28 Bayer Ag Trisubstituierte Biphenyle
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
IL129416A0 (en) 1996-10-14 2000-02-17 Bayer Ag New heterocyclylmethyl-substituted pyrazol derivatives
DE19649460A1 (de) 1996-11-26 1998-05-28 Bayer Ag Neue substituierte Pyrazolderivate
DE19834045A1 (de) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
AU6518299A (en) 1998-10-16 2000-05-08 Medical Solutions, Inc. Temperature control system and method for heating and maintaining medical items at desired temperatures
DE19920352A1 (de) 1999-05-04 2000-11-09 Bayer Ag Substituiertes Pyrazolderivat
DE60022508T2 (de) 1999-06-14 2006-06-08 Eli Lilly And Co., Indianapolis Inhibitoren von serin proteasen
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
HUP0203869A2 (hu) * 1999-12-21 2003-07-28 Pharmacia & Upjohn Co. Szulfoximin funkcionalitással rendelkező oxazolidinok és alkalmazásuk mikrobaellenes szerként, a vegyületeket tartalmazó gyógyszerkészítmények
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
GB0114004D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114005D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
TWI257389B (en) 2001-06-12 2006-07-01 Lilly Co Eli Pharmaceutical compound
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
CA2452513A1 (en) 2001-07-12 2003-01-23 Pharmacia & Upjohn Company Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound
CA2461202C (en) 2001-09-21 2011-07-12 Donald Pinto Lactam-containing compounds and derivatives thereof as factor xa inhibitors
TW200738672A (en) 2001-12-10 2007-10-16 Bristol Myers Squibb Co Intermediated for the preparation of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
PE20040804A1 (es) 2002-12-19 2004-12-31 Boehringer Ingelheim Pharma DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa
US7205318B2 (en) 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
DE10322469A1 (de) 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclische Verbindungen
US7265140B2 (en) 2003-09-23 2007-09-04 Pfizer Inc Acyloxymethylcarbamate prodrugs of oxazolidinones
CA2545730C (en) 2003-11-12 2014-07-08 Daiichi Pharmaceutical Co., Ltd. Process for producing thiazole derivative
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
JP2005179272A (ja) 2003-12-19 2005-07-07 Yamanouchi Pharmaceut Co Ltd カルボキサミド誘導体のマロン酸塩結晶
DE102004002044A1 (de) 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
GB0405272D0 (en) 2004-03-09 2004-04-21 Trigen Ltd Compounds
KR101195801B1 (ko) 2004-06-18 2012-11-05 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｘａ 인자 억제제
US20060069260A1 (en) * 2004-09-28 2006-03-30 Huiping Zhang Preparation of N-aryl pyridones
DE102004062475A1 (de) 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
WO2006106804A1 (ja) 2005-03-31 2006-10-12 Mochida Pharmaceutical Co., Ltd. 環内窒素原子にアシル基が結合した三環系スピロ化合物
CN101218227A (zh) 2005-07-08 2008-07-09 阿斯利康(瑞典)有限公司 作为因子Xa的抑制剂的杂环磺酰胺衍生物
AR057976A1 (es) * 2005-08-29 2008-01-09 Boehringer Ingelheim Int Biarilos sustituidos y su uso como medicamentos.
DE102005047558A1 (de) 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005050497A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Difluorphenol-Derivate und ihre Verwendung
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
DE102005050375A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Tetrazol-Derivate und ihre Verwendung
DE102005050376A1 (de) 2005-10-21 2007-05-31 Bayer Healthcare Ag Dicarbonsäure-Derivate und ihre Verwendung
DE102005050498A1 (de) 2005-10-21 2007-06-06 Bayer Healthcare Aktiengesellschaft Cyclopropylessigsäure-Derivate und ihre Verwendung
DE102006025314A1 (de) 2006-05-31 2007-12-06 Bayer Healthcare Ag Arylsubstituierte Heterozyklen und ihre Verwendung
DE102006039589A1 (de) 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung

Also Published As

Publication number Publication date
ECSP099807A (es) 2010-01-29
DK2170877T3 (da) 2013-02-11
SI2170877T1 (sl) 2013-03-29
DOP2009000285A (es) 2010-01-31
KR20100021615A (ko) 2010-02-25
BRPI0813736A2 (pt) 2014-12-30
CL2008001691A1 (es) 2008-12-26
PE20090332A1 (es) 2009-04-09
CO6251281A2 (es) 2011-02-21
GT200900319A (es) 2011-11-09
AU2008266525B8 (en) 2013-09-19
AR066981A1 (es) 2009-09-23
MA31535B1 (fr) 2010-07-01
MX2009013711A (es) 2010-02-01
PA8784301A1 (es) 2009-02-09
RU2481345C2 (ru) 2013-05-10
JP5537421B2 (ja) 2014-07-02
CU20090216A7 (es) 2011-10-14
DE102007028319A1 (de) 2008-12-24
CA2692166C (en) 2015-01-27
ES2397799T3 (es) 2013-03-11
EP2170877A1 (de) 2010-04-07
UA98793C2 (ru) 2012-06-25
IL202351A (en) 2015-10-29
TWI413642B (zh) 2013-11-01
CR11168A (es) 2010-06-28
RU2010101307A (ru) 2011-07-27
CY1113580T1 (el) 2016-06-22
US8846934B2 (en) 2014-09-30
CN101821259B (zh) 2013-10-30
JO2798B1 (en) 2014-03-15
PT2170877E (pt) 2013-01-28
AR067057A1 (es) 2009-09-30
RS52639B (sr) 2013-06-28
EP2170877B1 (de) 2012-11-21
UY31133A1 (es) 2009-01-30
US20140057951A1 (en) 2014-02-27
HN2009003424A (es) 2012-01-05
SV2009003435A (es) 2010-08-23
KR101535312B1 (ko) 2015-07-09
JP2010530383A (ja) 2010-09-09
CA2692166A1 (en) 2008-12-24
HRP20130072T1 (hr) 2013-02-28
HK1147991A1 (en) 2011-08-26
PL2170877T3 (pl) 2013-03-29
TN2009000503A1 (en) 2011-03-31
SG182220A1 (en) 2012-07-30
US20100184740A1 (en) 2010-07-22
IL202351A0 (en) 2010-06-30
TW200911797A (en) 2009-03-16
CU23820A3 (es) 2012-06-21
AU2008266525A1 (en) 2008-12-24
AU2008266525B2 (en) 2013-09-05
CN101821259A (zh) 2010-09-01
NZ581540A (en) 2012-01-12
MY150931A (en) 2014-03-14
WO2008155032A1 (de) 2008-12-24
US8383822B2 (en) 2013-02-26

Similar Documents

Publication Publication Date Title
HUS2100009I1 (hu) Halauxifen-metil és piroxszulam kombinációja
DK2170877T3 (da) Substituerede (oxazolidinon-5-yl-methyl)-2-thiophen-carboxamider og anvendelsen heraf på området for koagulering
DK2185164T3 (da) Sammensætning og terapeutisk antitumorvaccine
SI2084151T1 (sl) Substituirani dihidropirazoloni za zdravljenje kardiovaskularnih in hematoloških bolezni
HRP20171612T2 (hr) Umrežujuće spojnice i njihova upotreba
CY2015013I1 (el) Αντι-μολυσματικες πυραμιδινες και χρησεις αυτων
EP3622814C0 (en) ANIMAL MODELS AND THERAPEUTIC MOLECULES
IL209738B (en) Combination of cannabidiol and tetrahydrocannabidinol (thc) for use in treating glioblastoma
HRP20160859T1 (hr) Modificirani proteini rsv f i postupci njihove upotrebe
BRPI0814330A2 (pt) métodos e kits cirúrgicos
HRP20180718T1 (hr) Oligopeptidni spojevi i njihova upotreba
BRPI0816789A2 (pt) Goji e inflamação
HUE046951T2 (hu) TFPI-inhibitorok és eljárás alkalmazásukra
DK2001556T3 (da) Thioninium-forbindelser og anvendelse deraf
DK2190991T3 (da) SDF-1-Bindende nucleinsyrer og anvendelsen deraf
EP2298365A4 (en) MEDICAL COMPOSITION AND MEDICAL KIT
HRP20190045T1 (hr) Metode i sastavi za liječenje upalne bolesti crijeva
EP2139325A4 (en) ANTI-ANGIOGENIC AGENTS AND METHODS OF USE
DK2252688T3 (da) Syntetiske phosphodiester-oligonukleotider og terapeutiske anvendelser deraf
DK2293846T3 (da) Depsipeptider og deres terapeutiske anvendelse
SI2341900T1 (sl) Medicinski proizvod in zdravljenje
BRPI0714318A2 (pt) Utilização de 2-benzoil-imidazopiridinas em terapêutica
DK2310383T3 (da) 2-oxo-alkyl-1-piperazin-2-onderivater, fremstilling deraf og terapeutisk anvendelse deraf
DK2154144T3 (da) Oligonukleotider og anvendelse deraf
PL2314609T3 (pl) Pochodne metastyny i ich zastosowanie